Company Karyopharm Therapeutics Inc.

KPTI

US48576U2050

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 11/12/2025 GMT			5-day change	1st Jan Change
7.000 ^USD	+8.02%		+18.44%	-31.00%

11-04	RBC Cuts Price Target on Karyopharm Therapeutics to $19 From $30, Keeps Outperform Rating	MT
11-03	Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE

Business description: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Companyâs product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Number of employees: 279

Sales by Activity: Karyopharm Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovering, Developing and Commercializing Drugs to Treat Cancer	108M	210M	157M	146M	145M

See all business segments

Geographical breakdown of sales: Karyopharm Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	108M	210M	157M	146M	145M

See all geographic segments

Executive Committee: Karyopharm Therapeutics Inc.

Manager	Title	Age	Since
Richard Paulson CEO	Chief Executive Officer	57	02/05/2021
Lori Macomber DFI	Director of Finance/CFO	54	02/01/2025
Amama Sadiq CTO	Chief Tech/Sci/R&D Officer	-	31/03/2023
Accumanno James CMP	Compliance Officer	-	30/04/2021
Reshma Rangwala CTO	Chief Tech/Sci/R&D Officer	47	31/03/2022

See KARYOPHARM THERAPEUTICS INC. governance

Composition of the Board of Directors: Karyopharm Therapeutics Inc.

Director	Title	Age	Since
Barry Greene BRD	Director/Board Member	61	31/12/2012
Deepa Pakianathan BRD	Director/Board Member	60	31/03/2013
Garen Bohlin BRD	Director/Board Member	77	02/10/2013
Richard Paulson BRD	Director/Board Member	57	25/02/2020
Christy Oliger BRD	Director/Board Member	55	27/08/2020
Chen Schor BRD	Director/Board Member	52	24/11/2020
Zhen Su BRD	Director/Board Member	48	30/08/2023

Composition of the Board of Directors

Shareholders: Karyopharm Therapeutics Inc.

Name	Equities	%	Valuation
T. Rowe Price Investment Management, Inc. 13.51 %	2,304,242	13.51 %	13 M $
Opaleye Management, Inc. 9.202 %	1,569,002	9.202 %	9 M $
J Wood Capital Advisors LLC 4.603 %	784,802	4.603 %	4 M $
T. Rowe Price Investment Management, Inc. 4.111 %	700,992	4.111 %	4 M $
Affinity Asset Advisors LLC 3.896 %	664,224	3.896 %	4 M $

List of KARYOPHARM THERAPEUTICS INC. shareholders

Company details: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics, Inc.

85 Wells Avenue

02459-3298, Newton

+617 658 0600

http://www.karyopharm.com

address Karyopharm Therapeutics Inc.(KPTI)

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KARYOPHARM THERAPEUTICS INC.	+8.02%	+18.44%	-35.99%	-90.07%	119M
REGENERON PHARMACEUTICALS, INC.	+2.84%	+3.32%	-3.39%	-0.43%	76.62B
CSL LIMITED	+2.86%	-0.09%	-33.92%	-38.32%	57.54B
UCB	-2.12%	-4.81%	+29.66%	+226.41%	53.75B
SAMSUNG BIOLOGICS CO.,LTD.	+0.24%	+66.90%	+66.90%	+66.90%	52.52B
BIOGEN INC.	-2.84%	-5.21%	+9.55%	-39.55%	25.31B
INCYTE CORPORATION	+0.98%	-4.34%	+32.57%	+16.71%	18.87B
INNOVENT BIOLOGICS, INC.	+1.85%	-7.39%	+123.62%	+166.25%	18.42B
ALTEOGEN INC.	-0.66%	-12.62%	+47.24%	+1,004.75%	16.49B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+57.21%	+154.72%	14.02B
Average	+1.07%	-0.07%	+29.35%	+146.74%	33.37B
Weighted average by Cap.	+0.65%	-0.80%	+22.80%	+103.54%